<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323414</url>
  </required_header>
  <id_info>
    <org_study_id>DK61732</org_study_id>
    <secondary_id>U01DK061732</secondary_id>
    <nct_id>NCT00323414</nct_id>
  </id_info>
  <brief_title>Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver</brief_title>
  <official_title>Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of&#xD;
      non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver&#xD;
      disease in developed countries. Among adults in the United States, the prevalence is between&#xD;
      5.7% and 17%. These rates are expected to increase concurrent with the epidemics of obesity&#xD;
      and type 2 diabetes mellitus, which are the major risk factors for NAFLD and NASH. In&#xD;
      addition to its high prevalence, NASH is also a progressive fibrotic disease that advances to&#xD;
      cirrhosis and liver related death in 20% and 12% of patients, respectively. Among NASH&#xD;
      patients with cirrhosis, 40% have liver related death. Diabetics are particularly prone to&#xD;
      experience these poor outcomes. No therapy has been proven effective for patients with NASH.&#xD;
&#xD;
      The purpose of this study is to find out whether treatment with polyunsaturated fatty acids&#xD;
      (eicosapentaenoic acid [EPA] combined with docosahexaenoic acid [DHA] called Opti-EPA)&#xD;
      improves NASH compared to treatment with placebo pills. The placebo pills will contain corn&#xD;
      oil and will be contained in a capsule, but have no medical effect on the body. The&#xD;
      investigators will determine improvement in NASH from microscopic changes in the subject's&#xD;
      liver tissue during 48 weeks of treatment. This means that the subject will need to have a&#xD;
      liver biopsy before and after the treatment.&#xD;
&#xD;
      Omega-3 fatty acids are a form of polyunsaturated fats, one of the four basic types of fat&#xD;
      that the body gets from food. (Cholesterol, saturated fat, and monounsaturated fat are the&#xD;
      others.) One's body does not make this type of fat; it comes from food sources. These fats&#xD;
      are found in foods like cold water fish (tuna, salmon, and mackerel), and vegetable products&#xD;
      like flaxseed oil and walnuts.&#xD;
&#xD;
      Research shows that polyunsaturated fats are good for people. Studies have shown that it is&#xD;
      good for heart health by playing a role in keeping blood cholesterol levels low, keeping&#xD;
      irregular heart rhythms stable, and reducing blood pressure.&#xD;
&#xD;
      The drug being studied, Opti-EPA, is a nutritional supplement. They do not have to be&#xD;
      reviewed by the Food and Drug Administration (FDA) like medicines do. Opti-EPA is considered&#xD;
      experimental in this study. This means that the United States Food and Drug Administration&#xD;
      (FDA) has not approved it for use in people with nonalcoholic fatty liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although there is no proven effective treatment of NASH, dietary supplementation with long&#xD;
      chain omega-3 polyunsaturated fatty acids (PUFA's) may be beneficial. This suggestion is&#xD;
      based on three previously reported observations: first, patients with NASH consume less PUFAs&#xD;
      and more saturated fats than subjects without NASH. Second, PUFAs are beneficial in patients&#xD;
      with hypertension and hypertriglyceridemia. Third, PUFAs decrease lipid peroxidation and&#xD;
      ameliorate hepatic steatosis in animal models of NAFLD.&#xD;
&#xD;
      We therefore hypothesize that the administration of these PUFAs, eicosapentaenoic acid (EPA)&#xD;
      and docosahexaenoic acid (DHA) will reduce hepatic fat content, inflammation and hepatic&#xD;
      injury in patients with type 2 diabetes mellitus who have NASH.&#xD;
&#xD;
      Aims&#xD;
&#xD;
      To determine in patients with type 2 diabetes mellitus who have NASH if dietary&#xD;
      supplementation with purified omega-3 fatty acids (EPA and DHA) will:&#xD;
&#xD;
        1. Decrease the histologic severity of NASH.&#xD;
&#xD;
        2. Alter the expression of genes important in the pathways of hepatic lipid synthesis and&#xD;
           oxidation.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Patients who meet the inclusion criteria will be randomized to receive omega-3 fatty acids or&#xD;
      placebo. Stratified randomization will be done based on the NASH Clinical Research Network&#xD;
      pathology score of 5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</measure>
    <time_frame>48 weeks</time_frame>
    <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase (AST) Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase (ALT) Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C Levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>Hemoglobin A1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Polyunsaturated fatty acid (Opti-EPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyunsaturated fatty acid (Opti-EPA)</intervention_name>
    <description>Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks</description>
    <arm_group_label>Polyunsaturated fatty acid (Opti-EPA)</arm_group_label>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age &gt;18 years)&#xD;
&#xD;
          -  Have type 2 diabetes mellitus with good control of blood sugar (hemoglobin A1c [HbA1c]&#xD;
             &lt;7.5%) and will have been on a stable regimen of anti-diabetic agents for more than 4&#xD;
             months.&#xD;
&#xD;
          -  NASH established on liver biopsy done within 6 months prior to inclusion in the study&#xD;
             as determined by established histologic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis of the liver&#xD;
&#xD;
          -  End stage target organ damage in diabetes mellitus: advanced renal failure (serum&#xD;
             creatinine &gt; 2.0 mg/dl) with or without dialysis, severe neuropathy, or advanced&#xD;
             peripheral vascular disease.&#xD;
&#xD;
          -  Any organ dysfunction with anticipated life expectancy of less than 2 years&#xD;
&#xD;
          -  Co-existent etiologies for liver disease&#xD;
&#xD;
          -  Significant alcohol consumption, defined as more than 30 g per day in men and more&#xD;
             than 20 g per day in women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur J. McCullough, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Srinivasan Dasarathy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jhucct.com/nash/</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Network</description>
  </link>
  <reference>
    <citation>Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5. Erratum in: Clin Gastroenterol Hepatol. 2004 Jun;2(6):522.</citation>
    <PMID>15017611</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2018</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PUFA</keyword>
  <keyword>NASH</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</title>
        <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of &gt;= 2 Points in NAFLD Activity Score (NAS)</title>
          <description>The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) is a score based on the liver biopsy. It represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8, with high scores indicating more activity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</title>
        <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values</title>
          <description>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) measures insulin resistance, calculated by fasting insulin (Î¼U/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.</description>
          <units>HOMA-IR index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="10.3"/>
                    <measurement group_id="O2" value="13.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Amino Transferase (AST) Levels</title>
        <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Amino Transferase (AST) Levels</title>
          <description>Aspartate amino transferase (IU/dL) at 48 weeks</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="17.4"/>
                    <measurement group_id="O2" value="47.9" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Amino Transferase (ALT) Levels</title>
        <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Amino Transferase (ALT) Levels</title>
          <description>Alanine amino transferase (IU/dL) ay 48 weeks</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="30.9"/>
                    <measurement group_id="O2" value="59.6" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucose Levels</title>
        <description>Fasting blood glucose</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Levels</title>
          <description>Fasting blood glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.4" spread="43.7"/>
                    <measurement group_id="O2" value="123.5" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1C Levels</title>
        <description>Hemoglobin A1c</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PUFA</title>
            <description>Active treatment with PUFA</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1C Levels</title>
          <description>Hemoglobin A1c</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.2"/>
                    <measurement group_id="O2" value="6.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>Patient reported adverse events and abnormal laboratory tests were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>PUFA</title>
          <description>Purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps 3 capsules by mouth 2x per day x 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post liver biopsy pain</sub_title>
                <description>End of treatment, post liver biopsy bleeding requiring blood transfusion in one and none in the other. Both patients showed evidence of perihepatic hematoma and were discharged home uneventfully</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Post liver biopsy bleeding</sub_title>
                <description>Needed 2 units blood transfusion. Discharged uneventfully and is being followed in the clinic subsequently</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICD 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>No tissue</sub_title>
                <description>Liver biopsy did not yield tissue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinivasan Dasarathy MD</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>216-444-2766</phone>
      <email>dasaras@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

